It is often noticed that investment experts ask people to diversify their money across sectors. More often than not, it is recommended that some attention should be allocated towards biotech stocks. The simple reason behind this is the fact that biotech stocks have proven to be fruitful companies and the sector continues to churn out winners.
However, an investor needs to do his research well in order to come up with a list of stocks to watch. Here is a look at three penny companies that could take a spotlight this month:
PharmaCyte Biotech (PMCB)
PharmaCyte Biotech (PMCB) is in the prep phase of clinical trials and readying to complete its Investigational New Drug Application for the FDA. Whether you’re new to biotech stocks or a seasoned vet, you should understand how important milestones like this are for a company.
David A. Judd, a cellular biologist and a member of PharmaCyte’s Medical and Scientific Advisory Board, was recently interviewed. Right now, PharmaCyte Biotech (PMCB) is putting together the necessary material for its planned clinical trial for inoperable pancreatic cancer, one of the most deadly forms of cancer today. Though there has been a targeted focus on Pancreatic cancer with PharmaCyte, its diabetes application may also have promise according to Judd.
“I think diabetes is where this type of technology really lends itself to the application. The key is to develop the right type of cell line to treat Type 1 and insulin-dependent Type 2 diabetes. There are several cell lines being explored by PharmaCyte simultaneously to do this. Selecting the right cell line to become our leading product candidate to treat diabetic patients in need of insulin is key to the success of PharmaCyte’s Diabetes Program.”
As one report puts it, “Clinical trials are essential for the development of new treatments, and PharmaCyte will enter this upcoming trial with two essential goals in mind—the future of its pancreatic cancer treatment and the future of its technology.”
For more on PharmaCyte, Click Here
CAN FITE (CANF)
The first biotech stock to consider is that of CAN FITE (CANF), which made a significant announcement and triggered a significant rally. The announcement is relating to its advanced hepatocellular carcinoma medicine named Namodenoson.
According to the announcement made by the company, the United States Food and Drugs Administration has given Can-Fite permission to design its Phase 3 clinical trial for the said product. It goes without saying that it is a significant development for the company and it is only natural that the stock rallied. The Can-Fite stock soared by as much as 12% in Thursday’s trading and should be on the watch lists of most investors at this point.
Catalyst Pharmaceuticals (CPRX)
The other biotech stock that could be worth looking at is that of Catalyst Pharmaceuticals Inc (CPRX). One of the most important projects for Catalyst was the medicine Fridapse, but this Wednesday the company had a setback after it failed to reach the primary endpoint. The stock crashed by as much as 13% after the news broke.
However, it is important to note that there could be some value in actually buying the dip. The company is going to release the data from the top line for Firdapse next year and if it manages to be successful then it is being estimated that the medicine could generate as much as $191 million in annual sales.
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and Complete Investment And Management LLC, a Non-affiliate Third Party, Midam was hired for a period from 07/09/2019 – 8/09/2019 to publicly disseminate information about PharmaCyte Biotech including on the Website and other media including Facebook and Twitter. We were paid $150,000 (CASH) for & were paid “0” shares of restricted common shares. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 8/12/2019 – 10/15/2019. We were paid an additional $150,000 (CASH) BY Complete Investment And Management LLC, a Non-affiliate Third Party, AND HAVE EXTENDED coverage for a period from 10/16/2019 – 11/15/2019.We may buy or sell additional shares of PharmaCyte Biotech in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.